#USA #New York #Levi & Korsinsky #Fractyl Health #GUTS

Investors on Alert: Potential Class Action Against Fractyl Health, Inc.

In a significant development for shareholders of Fractyl Health, Inc. (NASDAQ: GUTS), a securities class action has been initiated by Levi & Korsinsky, LLP on behalf of investors who suffered losses during a specific period. This lawsuit could provide an avenue for affected investors to seek recovery of their investment losses stemming from alleged inaccuracies and omissions surrounding the company's reported clinical efficacy data.

Background of the Case

Fractyl Health focuses on providing innovative treatments in the medical field, particularly targeting weight management solutions through their Revita DMR System. In September 2025, Fractyl boasted promising preliminary findings from their REMAIN-1 Midpoint Cohort study. They reported that patients who received Revita treatment lost 2.5% of body weight after stopping GLP-1 drugs. This led to heightened investor enthusiasm, resulting in the pricing of a 60 million share offering at $1.00 each just days later.

However, the optimism surrounding these claims diminished rapidly. By January 2026, a follow-up report revealed that Revita-treated patients had experienced a 4.5% weight regain, starkly contrasting with earlier claims and raising questions regarding the reliability of the initial data. Investors witnessed a drastic decrease in GUTS share prices, which tumbled nearly 75% from earlier highs, signifying potential operational issues that may have been inadequately communicated to the public.

Key Allegations in the Lawsuit

The core of the lawsuit centers around the assertion that Fractyl Health knowingly overstated its clinical, regulatory, and commercial prospects with respect to the Revita system. Levi & Korsinsky argues that the results reported in September were misleading, given that subsequent findings indicated operational challenges at one study site, which significantly affected the reported efficacy outcomes. These discrepancies present a case for the plaintiffs, as they highlight the gap between the initially reported promise and the actual results.

Specific Misstatements

• - Promised Efficacy: Initial claims suggested Revita would lead to an additional 2.5% weight loss post-GLP-1 discontinuation, while actual data reflected a more alarming 4.5% regain.
• - Transparency Issues: The lawsuit suggests there was a lack of disclosure regarding operational challenges that potentially compromised the integrity of the study data. A study site reportedly had insufficient lifestyle counseling and was not prepared to support a dietary intervention program, which undermined the study's results.

By January 29, 2026, GUTS shares fell sharply by over $1.24, closing at $0.585, followed by an additional decrease the very next day. The lawsuit aims to hold Fractyl accountable for its misleading information, which may have inflated stock prices during the class period.

Who Can Participate in the Class Action?

Investors who purchased Fractyl Health securities between January 13, 2025, and January 29, 2026, and experienced financial losses could be eligible for participation in the lawsuit. Documentation proving purchase dates, quantities, and prices paid will be essential for eligibility verification.

Despite being a difficult scenario, those who sold their GUTS shares at a loss during the class period might also join the proceedings. Importantly, interested parties are encouraged to review their brokerage records as initial participation doesn't require immediate financial commitment to assess potential recovery.

Next Steps for Interested Investors

• - Gather Documentation: Collect brokerage records showing purchase dates and transaction details.
• - Contact Legal Representation: Potential claimants can reach out to Levi & Korsinsky for a no-cost evaluation of their situation. Investors might have until the lead plaintiff deadline of October 20, 2026, to take action.

Conclusion

This class action represents a pivotal moment for investors impacted by Fractyl Health's controversies. With the marketplace shaken by recent events, stakeholders should remain vigilant and informed about their rights. By pursuing legal recourse, investors can hold companies accountable for transparency and ethical practices in their financial reporting.